This content is only available within our institutional offering.
26 Sep 2023
UCB - Big in Japan
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
UCB - Big in Japan
UCB (UCB:EBR), 0 | UCB S.A. (UCB:BRU), 0
- Published:
26 Sep 2023 -
Author:
David Seynnaeve, PhD -
Pages:
6
Last night, UCB announced approval of both RYSTIGGO® and zilucoplan ‘ZILBRYSQ®' for the treatment of generalysed myasthenia gravis (gMG) in Japan. ZILBRYSQ® is the 1st approved self-administered innovative gMG solution, allowing for administration at home thereby offering additional patient comfort and differentiating it from the competition, including ARGX's VYVGART® (Hytrulo).This 1st approval for zilucoplan adds a 2nd option to UCB's gMG treatment arsenal, following the June US approval of rozanolixizumab. We foresee these drugs to coexist (rather than cannabilize) since ZILBRYSQ® is intended to be used as a long-term maintenance treatment while RYSTIGGO® is positioned as an add-on treatment during